Autoantibodies Activating Human β ₁ -Adrenergic Receptors Are Associated With Reduced Cardiac Function in Chronic Heart Failure
Key result
Activating autoantibodies against human beta-adrenergic receptors were present in 26% of patients with dilated cardiomyopathy versus 1% in healthy subjects, and associated with poorer cardiac function.
Why the study?
Are autoantibodies activating human beta-1-adrenergic receptors associated with reduced cardiac function in patients with chronic heart failure?
Study Design
Type
Case-Control (n=212)
Structured PICO
Are autoantibodies activating human beta-1-adrenergic receptors associated with reduced cardiac function in patients with chronic heart failure?
P
Population
104 patients with dilated or ischemic cardiomyopathy (NYHA functional classes II to IV) and 108 healthy subjects
I
Intervention
Screening for IgG autoantibodies against human beta-1-adrenergic receptors and in vitro functional analysis
C
Comparator
Healthy subjects
O
Outcome
Prevalence of activating autoantibodies against human beta-adrenergic receptors and their association with left ventricular functionsurrogate
Main Result
Absolute Event Rate: 26% vs 1%
Activating autoantibodies against human beta-1-adrenergic receptors are present in a significant subset of patients with dilated cardiomyopathy and are associated with reduced left ventricular function, providing a potential mechanistic rationale for the efficacy of beta-blockers in heart failure.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Autoantibodies may mark higher-risk dilated cardiomyopathy; leaves open immunomodulatory strategies in heart failure.
Cite This Study
Jahns et al. (1999) conducted a case-control in Dilated or ischemic cardiomyopathy (n=212). Autoantibodies against human beta-1-adrenergic receptors vs. Healthy subjects was evaluated on Prevalence of activating autoantibodies against native human beta-adrenergic receptors. Activating autoantibodies against human beta-adrenergic receptors were present in 26% of patients with dilated cardiomyopathy versus 1% in healthy subjects, and associated with poorer cardiac function.